To date, oncogenic BRAF has been targeted with varying success scale in humans in melanoma, non-small cell lung cancer, colorectal carcinoma, and thyroid carcinoma, as well as gliomas and glioneuronal tumors. This evidence concerns the gene BRAF and non-small cell lung carcinoma.